The implications of waiving local clinical trials for drugs in India: a double-edged sword?
Saved in:
| Main Author: | Rajmohan Seetharaman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | The Lancet Regional Health - Southeast Asia |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772368224001513 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Double-Edged Sword of Anthropomorphism in LLMs
by: Madeline G. Reinecke, et al.
Published: (2025-02-01) -
Tocilizumab in COVID-19: A Double-Edged Sword?
by: Bartosz Kudliński, et al.
Published: (2024-12-01) -
The Double-Edged Sword of Vitamin A: Function and Toxicity
by: Paulina Grzeszczuk, et al.
Published: (2025-08-01) -
Pelota: A double-edged sword in virus infection
by: Xue Li, et al.
Published: (2025-07-01) -
Pelota: A double-edged sword in virus infection.
by: Xue Li, et al.
Published: (2025-07-01)